S&CO Inc. Invests $2.66 Million in Danaher Corporation $DHR

S&CO Inc. bought a new position in Danaher Corporation (NYSE:DHR) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 13,989 shares of the conglomerate’s stock, valued at approximately $2,664,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Norges Bank purchased a new stake in shares of Danaher in the fourth quarter worth about $2,177,106,000. Viking Global Investors LP grew its stake in Danaher by 543.9% during the second quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after acquiring an additional 2,455,994 shares in the last quarter. Wellington Management Group LLP increased its holdings in Danaher by 11.2% during the 4th quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock worth $3,451,380,000 after acquiring an additional 1,517,904 shares during the period. Capital International Investors increased its holdings in Danaher by 8.9% during the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after acquiring an additional 1,487,768 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Danaher by 9.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock valued at $3,656,595,000 after purchasing an additional 1,334,221 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DHR. Wolfe Research cut shares of Danaher from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. DZ Bank began coverage on Danaher in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 target price on the stock. Morgan Stanley lowered their price target on Danaher from $270.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Finally, Jefferies Financial Group reissued a “buy” rating and set a $245.00 price objective on shares of Danaher in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $228.91.

Danaher Stock Down 0.7%

Shares of NYSE:DHR opened at $202.51 on Friday. The firm has a market capitalization of $142.37 billion, a PE ratio of 35.97, a price-to-earnings-growth ratio of 2.52 and a beta of 0.78. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The firm has a fifty day moving average of $193.14 and a 200 day moving average of $193.21.

Danaher (NYSE:DHR) last released its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter last year, the business posted $0.77 earnings per share. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, research analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.